Bli medlem
Bli medlem

Du är här

2016-02-02

Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies

Monoclonal Antibodies

Agreement Further Supports Teva's Novel Biologics Development Program

JERUSALEM and VANCOUVER, British Columbia, 2016-02-02 14:00 CET (GLOBE
NEWSWIRE) --
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have
entered into a collaborative research agreement whereby AbCellera will apply
its high-throughput single cell antibody platform for the discovery of rare
monoclonal antibodies.

“We are pleased to work with AbCellera utilizing this company’s novel biologics
technology,” said Michael Hayden, MD, PhD, President of Global R&D and Chief
Scientific Officer at Teva. “This agreement will be complementary to our
existing antibody discovery process with the potential to strengthen Teva’s
capabilities in novel biologics discovery.”

Under the terms of the agreement, AbCellera will receive an upfront payment,
research payments, and is eligible to receive undisclosed downstream milestones
associated with the development and approval of therapeutic antibodies.

“These are tough problems that need new technologies to move them forward. Our
platform brings important advantages to enable the discovery of rare antibodies
with defined specificity and functional activity against difficult membrane
protein targets,” said Dr. Carl Hansen, President and CEO of AbCellera. “We
look forward to a close collaboration with the team of scientists at Teva, and
are excited at the chance to help advance this important program.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) is a leading global
pharmaceutical company that delivers high-quality, patient-centric healthcare
solutions to millions of patients every day. Headquartered in Israel, Teva is
the world’s largest generic medicines producer, leveraging its portfolio of
more than 1,000 molecules to produce a wide range of generic products in nearly
every therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous system,
including pain, as well as a strong portfolio of respiratory products. Teva
integrates its generics and specialty capabilities in its global research and
development division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more
information, visit www.tevapharm.com.

About AbCellera Biologics Inc.

AbCellera is a privately held company that has developed a high-throughput
platform for the rapid discovery of therapeutic antibodies directly from
natural immune cells. The company’s proprietary single cell technology can be
applied across multiple species and provides flexible assay formats to identify
antibodies with defined properties at a throughput of millions of B cells per
run. In addition to internal programs, AbCellera provides pharmaceutical and
biotechnology partners with access to state-of-the-art antibody discovery
capabilities to advance and accelerate therapeutic development. For more
information, visit http://www.abcellera.com.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of known and
unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our specialty products,
especially Copaxone® (including competition from orally-administered
alternatives, as well as from generic equivalents such as the recently launched
Sandoz product) and our ability to continue to migrate users to our 40 mg/mL
version and maintain patients on that version; our ability to identify and
successfully bid for suitable acquisition targets or licensing opportunities
(such as our pending acquisitions of Allergan’s generic business and Rimsa), or
to consummate and integrate acquisitions; the possibility of material fines,
penalties and other sanctions and other adverse consequences arising out of our
ongoing FCPA investigations and related matters; our ability to achieve
expected results from the research and development efforts invested in our
pipeline of specialty and other products; our ability to reduce operating
expenses to the extent and during the timeframe intended by our cost reduction
program; the extent to which any manufacturing or quality control problems
damage our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and restrictions
as well as credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property rights of
our specialty medicines; the effects of reforms in healthcare regulation and
pharmaceutical pricing, reimbursement and coverage; governmental investigations
into sales and marketing practices, particularly for our specialty
pharmaceutical products; adverse effects of political or economic instability,
major hostilities or acts of terrorism on our significant worldwide operations;
interruptions in our supply chain or problems with internal or third-party
information technology systems that adversely affect our complex manufacturing
processes; significant disruptions of our information technology systems or
breaches of our data security; competition for our generic products, both from
other pharmaceutical companies and as a result of increased governmental
pricing pressures; competition for our specialty pharmaceutical businesses from
companies with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities to
obtain U.S. market exclusivity for significant new generic products; potential
liability in the U.S., Europe and other markets for sales of generic products
prior to a final resolution of outstanding patent litigation; our potential
exposure to product liability claims that are not covered by insurance; any
failure to recruit or retain key personnel, or to attract additional executive
and managerial talent; any failures to comply with complex Medicare and
Medicaid reporting and payment obligations; significant impairment charges
relating to intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to the
capital markets; potentially significant increases in tax liabilities; the
effect on our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our business;
variations in patent laws that may adversely affect our ability to manufacture
our products in the most efficient manner; environmental risks; and other
factors that are discussed in our Annual Report on Form 20-F for the year ended
December 31, 2014 and in our other filings with the U.S. Securities and
Exchange Commission.

IR Contacts: Kevin C. Mannix United States (215) 591-8912
Ran Meir United States (215) 591-3033
Tomer Amitai Israel 972 (3) 926-7656
PR Contacts: Iris Beck Codner Israel 972 (3) 926-7687
Denise Bradley United States (215) 591-8974
Nancy Leone United States (215) 284-0213
AbCellera Contact: Kevin Heyries Canada (604) 827-4151

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.